The patent covers the design and production of HuCAL antibody library based on phage display
The Japanese Patent Office has granted MorphoSys a patent that provides extended protection for the biotechnology company's HuCAL technology. JP 4436457 covers the production and design of an antibody library based on phage display.
‘Important progress was made with our patent portfolio during 2009 and in the first quarter of 2010, including the issue of the first Japanese patents covering our core proprietary technologies HuCAL and CysDisplay,’ said Marlies Sproll, chief scientific officer of MorphoSys, headquartered in Germany. ‘Our growing patent estate in Asia complements our strong intellectual property portfolio around HuCAL in other key pharmaceutical markets.’
MorphoSys's HuCAL libraries are of highly diverse, fully human synthetic antibodies, whose modular CDR designs facilitate systematic engineering of antibody properties. The most advanced version of the technology, HuCAL Platinum, provides rapid access to fully human antibodies for use as research tools, diagnostics and therapeutics.